Peptide immunotherapy

Allergy: European Journal of Allergy and Clinical Immunology, Supplement

Volumn 54, Issue 56, 1999, Pages 45-46

  Muller U R ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN; HOUSE DUST ALLERGEN; IMMUNOGLOBULIN E; LYMPHOCYTE ANTIGEN;

ALLERGY; ANTIGEN PRESENTATION; ANTIGEN SPECIFICITY; CONFERENCE PAPER; HUMAN; IMMUNOGENICITY; IMMUNOGLOBULIN PRODUCTION; IMMUNOTHERAPY; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

ALLERGENS; ANIMALS; DESENSITIZATION, IMMUNOLOGIC; EPITOPES, T-LYMPHOCYTE; HUMANS; PEPTIDES;

EID: 0344995277     PISSN: 01081675     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (7)

1. Wallner BP, Gefter ML. Immunotherapy with T-cell-reactive peptides derived from allergens. Allergy 1994;49:302-308.
2. Briner T, Kuo M, Keating K, Rogers B, Greenstein J. Peripheral T-cell tolerance induced in naive and primed mice by subcutaneous injections of peptides from major cat allergen Fel d 1. Proc Natl Acad Sci USA 1993;90:1613-1628.
3. Hoyne G, O'Heir RE, Wraith D, Thomas WR, Lamb JR. Inhibition of T-cell and antibody responses to house dust mite allergen by inhalation of the dominant T-cell epitope in naive and sensitized mice. J Exp Med 1993;178:1783-1788.
4. Norman P, Ohman J, Long P, et al. Treatment of cat allergy with T-cell reactive peptides. Am J Respir Crit Care Med 1996;154:1623-1628.
5. 2. J Immunol 1993;150:3582-3591.
6. 2 induces specific T-cell anergy in patients allergic to bee venom. J Allergy Clin Immunol 1998;101:747-754.
7. 2 in bee venom immunotherapy and recovery by IL-2 and IL-15 in vitro. J Clin Invest 1996;98:1676-1683.